Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Boffito

Showing results (11-20 of 36) with videos related to

Pageof 4
Sort By:
European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V|August 7, 2013
Comparative evaluation of novel biodegradable nanoparticles for the drug targeting to breast cancer cellsC Mattu, R M Pabari, M Boffito, et al.
Current Medicinal Chemistry|December 17, 2008
Metabolic-inflammatory changes, and accelerated atherosclerosis in HIV patients: rationale for preventative measuresF De Lorenzo, S Collot-Teixeira, M Boffito, et al.
HIV Medicine|September 8, 2017
Out of focus: tailoring the cascade of care to the needs of women living with HIVA M Geretti, M Loutfy, A D'Arminio Monforte, et al.
HIV Medicine|June 29, 2017
InterPrEP: internet-based pre-exposure prophylaxis with generic tenofovir disoproxil fumarate/emtrictabine in London - analysis of pharmacokinetics, safety and outcomesX Wang, N Nwokolo, R Korologou-Linden, et al.
HIV Medicine|March 9, 2016
The role of tenofovir alafenamide in future HIV managementA Antela, C Aguiar, J Compston, et al.
International Journal of STD & AIDS|August 30, 2012
A dedicated clinic for HIV-positive individuals over 50 years of age: a multidisciplinary experienceL Waters, B Patterson, A Scourfield, et al.
Clinical Pharmacology and Therapeutics|July 19, 2012
Pharmacokinetic and pharmacodynamic analysis of efavirenz dose reduction using an in vitro-in vivo extrapolation modelM Siccardi, L Almond, A Schipani, et al.
Clinical Pharmacology and Therapeutics|September 28, 2007
Pharmacokinetics and safety of saquinavir/ritonavir and omeprazole in HIV-infected subjectsK Singh, L Dickinson, A Chaikan, et al.
Journal of Neurovirology|January 11, 2018
Correction to: CSF inflammatory markers and neurocognitive function after addition of maraviroc to monotherapy darunavir/ritonavir in stable HIV patients: the CINAMMON studyT J Barber, A Imaz, M Boffito, et al.
HIV Clinical Trials|April 30, 2016
A cross-sectional study to evaluate the association of hyperbilirubinaemia on markers of cardiovascular disease, neurocognitive function, bone mineral density and renal markers in HIV-1 infected subjects on protease inhibitorsT J Barber, G Moyle, A Hill, et al.
Pageof 4

Showing results (11-20 of 36) with videos related to

Sort By:
Pageof 4
European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V|August 7, 2013
Comparative evaluation of novel biodegradable nanoparticles for the drug targeting to breast cancer cellsC Mattu, R M Pabari, M Boffito, et al.
Current Medicinal Chemistry|December 17, 2008
Metabolic-inflammatory changes, and accelerated atherosclerosis in HIV patients: rationale for preventative measuresF De Lorenzo, S Collot-Teixeira, M Boffito, et al.
HIV Medicine|September 8, 2017
Out of focus: tailoring the cascade of care to the needs of women living with HIVA M Geretti, M Loutfy, A D'Arminio Monforte, et al.
HIV Medicine|June 29, 2017
InterPrEP: internet-based pre-exposure prophylaxis with generic tenofovir disoproxil fumarate/emtrictabine in London - analysis of pharmacokinetics, safety and outcomesX Wang, N Nwokolo, R Korologou-Linden, et al.
HIV Medicine|March 9, 2016
The role of tenofovir alafenamide in future HIV managementA Antela, C Aguiar, J Compston, et al.
International Journal of STD & AIDS|August 30, 2012
A dedicated clinic for HIV-positive individuals over 50 years of age: a multidisciplinary experienceL Waters, B Patterson, A Scourfield, et al.
Clinical Pharmacology and Therapeutics|July 19, 2012
Pharmacokinetic and pharmacodynamic analysis of efavirenz dose reduction using an in vitro-in vivo extrapolation modelM Siccardi, L Almond, A Schipani, et al.
Clinical Pharmacology and Therapeutics|September 28, 2007
Pharmacokinetics and safety of saquinavir/ritonavir and omeprazole in HIV-infected subjectsK Singh, L Dickinson, A Chaikan, et al.
Journal of Neurovirology|January 11, 2018
Correction to: CSF inflammatory markers and neurocognitive function after addition of maraviroc to monotherapy darunavir/ritonavir in stable HIV patients: the CINAMMON studyT J Barber, A Imaz, M Boffito, et al.
HIV Clinical Trials|April 30, 2016
A cross-sectional study to evaluate the association of hyperbilirubinaemia on markers of cardiovascular disease, neurocognitive function, bone mineral density and renal markers in HIV-1 infected subjects on protease inhibitorsT J Barber, G Moyle, A Hill, et al.
Pageof 4